CLINICAL EXPERIENCE WITH CEFIXIME IN URINARY TRACT INFECTIONS

• Published in: Japanese journal of antibiotics Vol. 42; no. 12; pp. 2540 - 2547
• Main Authors: KAMEOKA, HIROSHI, TAKANO, YUJI, MIYOSHI, SUSUMU, IWAO, NORIO, MIZUTANI, SHUTARO
• Format: Journal Article
• Language: Japanese
• Published: Japan Japan Antibiotics Research Association 01.12.1989
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections - drug therapy; Cefixime; Cefotaxime - adverse effects; Cefotaxime - analogs & derivatives; Cefotaxime - therapeutic use; Cystitis - drug therapy; Drug Evaluation; Female; Humans; Male; Middle Aged; Urinary Tract Infections - drug therapy
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.42.2540

Cefixime (CFIX, Cefspan®) a, new oral cephem, was used in the treatment of urinary tract infections, and was evaluated for its therapeutic effectiveness and safety at the Department of Urology, Osaka Rosai Hospital. In a total 129 cases, to which daily doses of 200 mg of CFIX were divided into 2 doses and administered clinical efficacies in 35 cases of women with acute uncomplicated cystitis treated for 3.9 days in average and 79 cases with complicated urinary tract infections (UTIs) treated for 5.9 days in average were assessed, according to the Criteria for Evaluation of Clinical Efficacy of Antimicrobial Agents on UTI (3rd ed.) recommended by the Japan UTI Committee with our own minimum modifications. Mid term urine and catheterized urine were examined as urine samples for bacteriological evaluation. Clinical efficacies in 35 cases with acute uncomplicated cystitis were excellent in 24 (69%) and moderate in 11 (31%), with an overall clinical efficacy rate of 100%. Clinical efficacies in 79 patients with complicated UTIs were excellent in 24 (30%), moderate in 26 (33%) and poor in 29 (37%), with an overall clinical efficacy rate of 63%. All of the 35 bacterial strains isolated from urine samples of uncomplicated UTIs patients were totally eradicated by the CFIX treatment, while 85 strains (79%) were eradicated among 107 strains isolated from urine samples of complicated UTIs patients. Subjective adverse reactions were observed in 4 cases (3.1%) out of a total of 128 patients, as general malaise in 1 and lower abdominal symptoms in 3 were recorded. All of them disappeared after the termination of CFIX administration. In conclusion, CFIX is considered as a clinically useful oral antibiotic in the treatment of UTI.